Is Thymosin Alpha-1 Legal in South Carolina? How to Access It Legally
Key numbers
- 17 noAdvisory committee members voting no on adding it to the pharmacy bulks list, December 4, 2024Source: fda.gov, as cited Nov 7, 2026
- 4 yesAdvisory committee vote count on the free base and acetate, December 4, 2024Source: fda.gov, as cited Nov 7, 2026
- 1.6 mgZadaxin dose per vial, sold outside the U.S. and not interchangeable with bulk powderSource: fda.gov, as cited Nov 7, 2026
At a glance
- FDA approval / None in the U.S.; four orphan designations are not approvals [1]
- State-licensed pharmacies and physicians / In none of the three categories, list updated May 14, 2026 [2]
- Outsourcing facilities / Category 3, 'nominated without adequate support', updated March 21, 2025 [3]
- Advisory committee vote / 4 yes, 17 no on both the free base and the acetate, December 4, 2024 [5]
- Safety-risk page / Now in the 'nominated but withdrawn' table; immunogenicity concerns remain posted [6]
- HHS peptide policy / Not among the six peptides in the October 2026 draft policy [4]
- Other countries / Zadaxin is approved in Italy, India and Hong Kong [1]
Is any thymosin alpha-1 product FDA-approved?
No. FDA found no U.S. application for thymosin alpha-1, also called thymalfasin [1]. It holds four U.S. orphan drug designations, but orphan designation is a separate process and is not an approval [1].
Zadaxin is the brand of finished injection sold outside the U.S. at 1.6 mg per vial, and it is not interchangeable with bulk thymosin alpha-1 powder [1]. FDA lists approvals in Italy, where it is an adjuvant to influenza vaccination in immunocompromised people, in India for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication, and in Hong Kong [1]. The European Medicines Agency has granted only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].
What do the federal compounding records show?
For state-licensed pharmacies and physicians, thymosin alpha-1 appears in none of the three categories on FDA's bulks list, updated May 14, 2026 [2]. For outsourcing facilities, FDA's list updated March 21, 2025 places it in category 3, 'nominated without adequate support' [3]. FDA's category 1 policy, under which it generally does not act against compounders if conditions are met, does not apply to it [2][3].
FDA proposed that thymosin alpha-1 not be added to the pharmacy bulks list. On December 4, 2024 the Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate; members who voted no cited no compelling evidence of clinical effectiveness and safety [5].
The safety-risk page, content dated 04/22/2026, lists it in the 'nominated but withdrawn' table. It had been in category 2 and came off because the nominators withdrew, but FDA's stated concerns remain posted: significant risk of immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information inadequate for the agency to understand the extent of any safety issues [6].
Thymosin alpha-1 is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [4]. No FDA or HHS action allowing its compounding has been identified [4].
What does that mean for access in South Carolina?
Federal records do not settle whether a South Carolina pharmacy may prepare or dispense thymosin alpha-1, because they do not address South Carolina law or the requirements of the South Carolina Board of Pharmacy [1][2][3][4].
FDA's compounding page says compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness or quality before they are marketed, so any compounded thymosin alpha-1 would carry that status [7].
Questions worth asking
Is thymosin alpha-1 banned in sport?
It is not named on WADA's 2026 Prohibited List and is not named in the 2027 List [8]. WADA does name thymosin-beta-4 and its derivatives such as TB-500 in S2.3, a different peptide [8]. S0 covers substances with no approval from any governmental health authority, and thymosin alpha-1 is approved in some countries [1][8].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is thymosin alpha-1 legal in South Carolina?
Is thymosin alpha-1 FDA-approved?
Is thymosin alpha-1 on FDA's compounding lists?
Where is Zadaxin approved?
Is thymosin alpha-1 banned by WADA?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
Where can I get thymosin alpha 1?
There is no FDA-approved U.S. product and no FDA or HHS action allowing thymosin alpha-1 to be compounded, so federal records give no clear legal route to it in South Carolina. Whether a South Carolina pharmacy may prepare or dispense it depends on South Carolina law and the South Carolina Board of Pharmacy, which the federal records do not address.
Is there another name for thymosin alpha 1?
Yes, it is also called thymalfasin. Zadaxin is a brand of finished injection sold outside the U.S. at 1.6 mg per vial, and it is not interchangeable with bulk thymosin alpha-1 powder.
References
Show all 8 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- U.S. Food and Drug Administration.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Compounding and the FDA: Questions and Answers | FDA.
- World Anti-Doping Agency.